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to TMA, the effect sizes were significantly larger in NMA. ConClusions: Network 
meta-analysis of multiple sclerosis trials shows fingolimod as the best treatment. 
Compared to traditional meta-analysis, network meta-analysis enables more robust 
estimation of effect sizes.
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PoSTherPeTic neurAlgiA (Phn) in chinA uSing A SimulATion model
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objeCtives: Peripheral neuropathic pain (pNeP) refers to the pain associated with 
the condition of peripheral neuropathy. Postherpetic neuralgia (PHN) is one type of 
pNeP, which is the most common complication of herpes zoster. This study aims to 
determine the effectiveness of pregabalin compared with gabapentin in pNeP and 
PHN in China. Methods: We utilized a 12-week simulation model which tracked 
a cohort of 1,000 patients with pNeP or PHN only, by pain score. A pre-treatment 
distribution of pain scores was collected utilizing a local questionnaire of Chinese 
KOLs for pNeP and PHN. Treatment outcomes for pregabalin (150 – 600 mg) and 
gabapentin (2,400 mg) were taken from the published literature. Results: In the 
PHN scenario, pregabalin was associated with a lower average pain score compared 
with gabapentin (3.92 vs. 4.52). The difference in mean days of no or mild pain, mod-
erate pain, and severe pain were 8.82, -5.74, and -3.06, when comparing pregabalin 
and gabapentin, respectively. Pregabalin had more mean days with a > 30% (7.71 
days), 40% (8.97 days), and 50% reduction (9.97 days) in pain when compared with 
gabapentin. In the pNep scenario, pregabalin was associated with a lower average 
pain score compared with gabapentin (3.91 vs. 4.55). The difference in mean days 
of no or mild pain, moderate pain, and severe pain were 9.39, -5.56, and -3.82, when 
comparing pregabalin and gabapentin, respectively. Pregabalin had more mean days 
with a > 30% (8.77 days), 40% (9.81 days), and 50% reduction (10.55 days) in pain when 
compared with gabapentin. ConClusions: Pregabalin is an effective treatment for 
PHN and even for pNeP extensively. It leads to improved outcomes including lower 
pain scores and more days with no or mild pain.
PSY12
fAcTor conSumPTion for ProPhYlAxiS And TreATmenT of Bleeding: 
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objeCtives: We studied the potential for new extended-half-life recombinant fac-
tor IX (rFIX) treatments to reduce the burden of injections and to prevent bleeding. 
We indirectly compared annualized bleed rates (ABRs) and factor consumption 
(FC) during prophylaxis and the FC and number of injections to treat a bleed with 
rFIX Fc fusion protein (rFIXFc) and conventional rFIX products based on estimates 
from published literature. Methods: A systematic review identified studies of 
routine prophylaxis in previously treated adults and adolescents with severe hae-
mophilia B for comparison with rFIXFc (Powell 2013; Arm 1, weekly prophylaxis). 
Comparisons were based on simple differences between studies in median weekly 
FC and mean ABRs during prophylaxis, and the median FC and numbers of injec-
tions per bleed. Median weekly FC during prophylaxis was reported or estimated 
from the reported dose and weekly number of injections; FC per bleed was esti-
mated from the reported dose and number of injections per bleed. The number 
of injections per bleed was calculated from the reported breakdown of bleeds 
by required number of injections or total number of injections divided by total 
bleeds. Results: Three conventional rFIX studies were included: Roth 2001 and 
Lambert 2007 (BeneFIX®) and Windyga 2014 (Rixubis®). During prophylaxis, the 
mean ABR was comparable or lower and FC was lower with rFIXFc compared with 
rFIX (weighted average ABR with rFIX= 4.0 vs. 3.1 with rFIXFc; weighted average 
increase in median weekly FC with rFIX= 108%). The number of injections and FC 
per bleed were also lower with rFIXFc (weighted average number of injections with 
conventional rFIX= 1.5 vs. 1.1 with rFIXFc; weighted average increase in median 
FC per bleed with rFIX= 49%). ConClusions: Indirect comparisons of published 
study results suggest that, compared with conventional rFIX, rFIXFc may require 
reduced FC for prophylaxis and bleed treatment while maintaining similar bleed-
ing rates for patients receiving prophylaxis.
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objeCtives: To model the impact of potential differences in adherence to rou-
tine prophylaxis with extended-half-life vs. conventional factor VIII and IX on 
bleeding efficacy for patients with severe haemophilia. Methods: Systematic 
literature reviews identified studies of routine prophylaxis in patients with severe 
haemophilia with conventional recombinant factor VIII (rFVIII) and IX (rFIX) for 
comparison with published studies of two extended-half-life agents (rFVIII and 
rFIX Fc fusion protein, rFVIIIFc and rFIXFc). We developed a model that extrapo-
lates the ABR for a given adherence level as the weighted average of two ABRs from 
clinical trials: those associated with prophylaxis (interpreted in the model as ABR 
associated with 100% adherence) and episodic treatment (interpreted as the ABR 
associated with 0% adherence). We used the model to extrapolate ABRs for con-
ventional products assuming real-world adherence of 76% of clinical trial levels, 
and ABRs for rFVIIIFc and rFIXFc at simulated adherence levels ≥ 76%. Extrapolated 
ABRs were compared using simple differences. We also mapped simulated adher-
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SYSTemATic revieW of economic evAluATionS in mulTidiSciPlinArY 
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objeCtives: The objective of this literature review was to explore the existing 
evidences regarding the economic evaluation of multidisciplinary pain man-
agement services in managing people with fibromyalgia or chronic widespread 
pain Methods: Electronic search of Embase, MEDLINE, PsychoINFO, NHS EED, 
JBI, and Cochrane database was performed. Studies published from the time of 
the respective database inception to April 2015 were considered for inclusion in 
this review. The quality of studies was assessed using the Cochrane Back Review 
Group and the Consolidated Health Economic Evaluation Reporting Standards 
(CHEERS). Results: The literature review allowed retrieving 620 studies of which 
6 fulfilled the eligibility criteria. All included studies were economic evaluations 
alongside randomized clinical trials published between 1996 and 2015. Two were 
from the UK, two from Spain, and two from the Netherland. Risk of bias was high 
in two studies. The intervention, comparators, disciplines involved, and number of 
sessions were well described in most of the studies. variation between the included 
studies were in type of interventions, length of administration, follow-up period, 
and outcome measured. None of the studies met all CHEERS quality criteria. In 
Five studies, multidisciplinary pain management services were cost-effective at 
short-term follow up; however, this was not always maintained in long term follow-
up. ConClusions: Due to the high level of heterogeneity among selected studies, 
we were unable to make a definitive conclusion about the cost-effectiveness of 
pain management services in managing people with fibromyalgia or chronic wide-
spread pain. Multidisciplinary pain management services trials must be based on 
high methodological and economic quality to determine the cost-effectiveness of 
multidisciplinary pain management services.
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objeCtives: To better understand the impact of new extended-half-life recom-
binant factor VIII (rFVIII) treatments relative to conventional rFVIII, we indirectly 
compared published clinical study results of the factor consumption (FC) and num-
ber of injections to treat a bleed during episodic therapy and the FC and annualized 
bleeding rates (ABR) during prophylaxis with rFVIII Fc fusion protein (rFVIIIFc) and 
conventional rFVIII. Methods: A systematic review identified studies of routine 
prophylaxis in previously treated adults and adolescents with severe haemophilia 
A for comparison with rFVIIIFc (Mahlangu 2014, Arm 1, individualized prophylaxis). 
Comparisons were based on the simple differences between studies in median 
weekly FC, mean prophylaxis ABRs, and the median FC and numbers of injections 
per bleed. Median weekly FC was reported or estimated from the reported dose and 
weekly number of injections; FC per bleed was estimated from the reported dose 
and number of injections per bleed. The number of injections per bleed was calcu-
lated from the reported breakdown of bleeds by required number of injections or 
the total number of injections divided by total bleeds. Results: Four conventional 
rFVIII studies were included: Tarantino 2004 and Valentino 2012 (Advate®), Recht 
2009 (Xyntha®), and Pollmann 2007 (REFACTO®). ABR and weekly FC during proph-
ylaxis were lower with rFVIIIFc compared with each conventional rFVIII study 
(weighted average mean ABR with rFVIII= 5.2 vs. 2.9 with rFVIIIFc; weighted average 
increase in median weekly FC with rFVIII= 24%). The number of injections and FC 
per bleed were comparable or lower with rFVIIIFc vs. each rFVIII study (weighted 
average number of injections with rFVIII= 1.4 vs. 1.2 with rFVIIIFc; weighted aver-
age increase in median FC per bleed with rFVIII= 43%). ConClusions: Based on 
estimates from published literature, rFVIIIFc requires reduced FC for prophylaxis 
and bleed resolution compared with conventional rFVIII while maintaining similar 
or decreased bleeding rates for patients receiving prophylaxis.
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objeCtives: Several new agents have shown positive results in clinical trials for 
prevention of relapses in multiple sclerosis. The objective of this study was to com-
pare network meta-analysis results with traditional meta-analysis. Methods: A 
systematic literature search for randomized clinical trials for multiple sclerosis 
was undertaken for the databases Pubmed, Embase, Biosis, Google Scholar and 
Cochrane. Data was collected for the study type, methods, country and key find-
ings. Extracted study data included study design, patient charatcertristcis and MS 
related outcomes. A bayesian random effects network meta-analysis (NMA) model 
was developed in WinBUGS14. Results were compared to previously published tra-
ditional meta-analysis (TMA). Results: We identified 730 references and found 
10 randomized trials in 4095 patients with 2518 events. The drugs included in our 
study were interferon (IFN), glatiramer (GLAT, natalizumab (NAT) and fingolimod 
(FING). The Odds Ratios (ORs) for FING versus NAT was 1.66 (0.31 – 9.96),FING versus 
GLAT 2.19 (0.50 – 7.49), FING versus IFN 2.25 (0.90 – 5.57), FING versus PLB 4.42 (1.46 
– 14.87), NAT versus GLAT 1.32 (0.22 – 5.40), NAT versus IFN 1.321.35 (0.29 – 5.75), 
NAT versus PLB 2.68 (0.71 – 9.99), GLAT versus IFN 1.03 (0.42 – 3.16), GLAT versus 
PLB 2.04 (0.95 – 5.91), IFN-B versus PLB 1.97 (1.01 – 4.14). The probability to be best in 
preventing relapses was 75.9% for FING, 17.0% for NAT and 6.3% for GLAT. Compared 
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we used the Medicare LDS 5% sample including years 2011-2013. MG patients 
were identified using the ICD-9 code 358.0 and were required to have at least two 
diagnoses. MG patients were indexed in the year 2012 and followed for a period of 
one year to assess costs and healthcare utilization. Results: We identified 2,047 
MG, 1,050 male and 997 female, patients in the Medicare sample giving a prevalence 
of 77/100,000. Male and female prevalences were 68 and 87/100,000, respectively. On 
average, male patient were older than females by 2.66 years (p= 0.01), had higher 
CCI scores (2.59 males, 2.21 for females, p= 0.01) and were less likely to be receiving 
Medicare disability benefits (16.67% and 25.68%, p= 0.01). Female MG patients were 
more frequently in the highest category for inpatients stays (12.94%, 9.14%, p= 0.03) 
and ER visits (36.81%, 31.81%, p= 0.01). ConClusions: Among Medicare beneficiar-
ies MG is more prevalent than in the US population. Large differences seen in the 
literature between male and female patients were not seen, most likely due to the 
specific nature of the Medicare beneficiary population. Female MG patients had 
higher rates of healthcare utilization, but cost differences were negligible.
PSY17
SickneSS fundS dATA AnAlYSeS on PrevAlence & incidence And 
TreATmenT of WAldenSTrom’S mAcrogloBulinemiA (Wm) in germAnY
Leisten M, Tomeczkowski J
Janssen-Cilag GmbH, Neuss, Germany
objeCtives: To determine the incidence and prevalence of patients diagnosed 
with MW (with or without other diagnoses of cancer) and to determine rate and 
type of chemotherapy and care settings using sickness data. Methods: Data 
from 1,771,217 beneficiaries in 2012 were analysed. A patient was incident for WM 
if no diagnosis was coded in 2010. WM patients were identified by ICD-10 C88.0, 
oncological co-diagnoses by ICD-10, chemotherapy by Anatomical Therapeutic 
Chemical (ATC) Code L01*, pharmacy number (PZN) 9999092 and/or operating and 
procedure code (OPS) 8-54*. Results: 108 patients with a diagnosis C88.0 could 
be identified (prevalence 0.0060%). 22 (20.4%) of them had their first diagnosis 
in 2012 (incident). Overall gender ratio was 56.5% male and 43.5% female. The 
highest share of patients was found in the age class 70-79 (41.7%). Additional 
oncological diagnoses were found in 67 (62.0%) patients diagnosed with WM. Top 
3 reported oncological disorders were: 61 (41.5%) had neoplasms with unknown 
behaviour (D37-48), 40 (27.2%) had a melanoma (C43-44) and 10 (6.8%) had malig-
nant neoplasms of male genital organs (C60-63). The outpatient diagnosis rate for 
WM was 84.3%, inpatient rate 3.7% and in- and outpatient rate 11.1%. 10 of the 
108 patients (9.3%) started chemotherapy in 2012 (30.0% out- and inpatient and 
70.0% outpatient). 3 of the incident patients (n= 22) started chemotherapy (13.6%) 
and 7 of the prevalent (n= 86, 8.1%). 6 patients received first-line (1 monotherapy) 
and 4 second-line treatment. Prescribed compounds were identified by ATC (out-
patient only): 75.9% rituximab, 48.3% bendamustine, 20.7% chlorambucil, 17.2% 
cyclophosphamide, 6.9% fludarabine and 6.9% vincristine (data suggesting com-
binations). ConClusions: The yearly chemotherapy rate was 9.3%. The major-
ity of the patients received no chemotherapy (n= 98, 90.7%). Most of the patients 
were diagnosed and treated in the outpatient sector. Oncological disorders were 
relatively high (62.0%).
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objeCtives: Obesity is a major risk factor for the development of multiple acute 
and chronic illnesses such as diabetes, cardiovascular diseases, stroke, and cancer. 
In order to improve targeting of resources for weight loss intervention, this study 
identified subgroups in a generalizable population who currently have the lowest 
rates of weight loss. Methods: This is a population-based retrospective observa-
tional study that assessed measured weight loss in 2014 among adolescents (13-17 
years old) and adults (25 years and older) members of Clalit Health Services (Clalit), 
the largest health maintenance organization in Israel, who were documented as 
obese (95 percentile and above for adolescents and BMI≥ 30 for adults) between 2010 
and 2014. Results: There are more than 14,000 adolescents and 420,000 adults, 
9.8% and 23.6% of the population in 2014 respectively, who were documented as 
obese between 2010 and 2014. Of those, in 2014, 13.2% adolescents and 13.5% adults 
no longer met the criteria for obesity. This change in BMI differed by age for both 
boys and girls, from 2.2% for those aged 13 to 17.4% for those aged 17, and from 3.8% 
for those aged 13 to 20.9% for those aged 17, respectively. Among adults, transition 
from obesity was the lowest among women in the 45-54 year age group (10.5%). 
Those with the lowest socioeconomic status also had lower rates compared to the 
highest socioeconomic status (11.4% vs. 15.4%, respectively for adolescents and 
11.9% vs. 16.7% for adults). ConClusions: As of 2014, less than 20% of the obese 
population has lost sufficient weight to not be considered obese. Members from 
low socioeconomic status and midlife-age women have the lowest reducing weight 
rates. Therefore, healthcare providers and weight loss interventions should consider 
focus on those populations.
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objeCtives: Anemia is one of the most commonly occurring hematological disor-
der in Indian women. The estimation of anemia prevalence in Indian women helps 
the health policy makers. The objective of the present study is to prevalence, severity 
of anemia among women in India. Methods: A systematic literature search was 
performed in PubMed and Elsevier ScienceDirect, Cochrane library databases and 
Google scholar (from 1990 to April 2015). All the eligible studies with full text and 
satisfy the inclusion criteria were included for study. Study consist of women in age 
ence improvements into changes in Validated Haemophilia Regimen Treatment 
Adherence Scale for Prophylaxis (VERITAS-Pro) scores, allowing us to illustrate 
specific aspects of adherence improvements with extended-half-life products 
potentially associated with significant reductions in ABRs. Results: Extrapolated 
ABRs for rFVIII and rFIX at 76% adherence were 12.7 and 7.4, respectively. The 
extrapolated rFVIIIFc ABR was significantly lower vs. conventional rFVIII for adher-
ence levels > 82% (Δ ABR > 3.0, P< 0.05). The extrapolated rFIXFc ABR was signifi-
cantly lower vs. conventional rFIX for adherence levels > 85% (Δ ABR > 2.0, P< 0.05). 
Depending upon initial adherence levels, our estimates suggest these adherence 
improvements are comparable to improvements in VERITAS-Pro total scale of 5-22 
points. ConClusions: Simulations using a model to understand the relation-
ship between adherence and ABR suggest improved adherence to prophylaxis 
associated with rFVIIIFc and rFIXFc may lead to significant reductions in bleeding 
rates.
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objeCtives: This systematic review aims to summarise and critically appraise 
the current evidence for the cost effectiveness of multidisciplinary pain man-
agement services in managing chronic back pain. Methods: Electronic search 
was conducted in three clinical databases, which include: MEDLINE, EMBASE and 
PsycINFO (using Ovid interface) from their inception to March 2015.Other data-
bases such NHS Economic Evaluation Database (NHS EED) and Health Technology 
Assessment Database (HTA) in the Centre for Reviews and Dissemination (CRD), 
were also explored to retrieve economic evaluation studies. The quality of ran-
domised clinical trials was assessed by Cochrane Back Review Group (CBRG) risk 
assessment tool. Consolidated Health Economic Evaluation Reporting Standards 
(CHEERS) checklist was used to assess the methodological quality of reporting eco-
nomic studies. Results: Five studies fulfilled our eligibility criteria. All of them 
were economic evaluations alongside randomised clinical trials. Two studies were 
from Norway, two from the Netherlands and one from the United Kingdom. These 
studies were published between 2002-2014. Two out of Five studies were consid-
ered having “low risk of bias). Three cost effectiveness studies showed that multi-
disciplinary pain management services were cost effective compared with usual 
care and surgery. The remaining studies showed that these services were not cost 
effective. ConClusions: Current evidence is inadequate to determine the cost 
effectiveness of multidisciplinary pain management services due to the variability 
of the interventions, comparators and outcomes.
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PrevAlence of AnTidePreSSAnTS PreScriBed To TrAmAdol uSerS in 
The uk PrimArY cAre SeTTing - A PreScriPTion Sequence SYmmeTrY 
AnAlYSiS
Chen T, Chen L, Knaggs RD
University of Nottingham, Nottingham, UK
objeCtives: In the past decade, there was a marked increase in the number of 
tramadol-related deaths in the UK, and these fatalities occurred in persistent trama-
dol users prescribed antidepressants concomitantly. However, the prevalence of 
such combinations has not been explored in the UK. This study took a prescription 
sequence symmetry analysis approach to explore the prevalence of antidepres-
sants prescription before and after the initiation of tramadol. Methods: This 
retrospective cohort study used the Clinical Practice Research Datalink. Patients 
who were prescribed tramadol from 2000 to 2011 were identified and prescriptions 
of tramadol and antidepressants were followed 9 years before and after the date 
of the first tramadol prescription. Patients who were issued at least one tramadol 
prescription consecutively in each follow-up patient year were defined as persistent 
users. The proportions of tramadol users combined with antidepressants before 
and after tramadol initiation were compared by Chi square test and stratified by 
non-persistent and persistent tramadol users. Results: Of the 526,624 included 
tramadol users, 22,003 (4.2%) were persistent users. The proportion of co-prescribing 
antidepressants in tramadol users significantly increased from 44.1% to 49.3% after 
the initiation of tramadol (P< 0.001). Of those co-prescribed with antidepressants, 
the proportions of co-prescribing tricyclic antidepressants and selective serotonin 
reuptake inhibitors (SSRIs) were higher than other antidepressants. After tramadol 
initiation, proportions of co-prescribing SSRIs changed +0.2% and -1% in persis-
tent and non-persistent groups, respectively. Comparing to persistent group, the 
prevalence of co-prescribing SSRIs was higher in non-persistent groups (56.2% vs. 
49.9%) after tramadol initiation. ConClusions: The increased prevalence of co-
prescription of antidepressants after initiation of tramadol shows that adverse 
drug-drug interactions might be underestimated by prescribers. Further studies 
are needed to evaluate the impact of such co-prescription on clinical outcomes 
and resource utilisation.
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objeCtives: Myasthenia Gravis (MG) is a rare neuromuscular disease affecting an 
individual’s voluntary muscular control. It is estimated that the US prevalence of 
MG is 20/100,000, however there is little information specifically focused on older 
adults. Evidence suggests that MG impacts men and women differently with women 
having an earlier onset of disease than men. We calculated the prevalence of MG 
among Medicare beneficiaries and assessed differences in patient characteristics 
and costs between male and female patients. Methods: To complete our study 
